Pharmaceutical Technology
FEBRUARY 23, 2023
Biopharmaceutics is a scientific discipline that examines the interrelationship of the physicochemical properties of the drug, the dosage form in which the drug is given, and the route of administration on the rate and extent of systemic drug absorption ( Applied Biopharmaceutics and Pharmacokinetics, Shargel, Wu-Pong and Yu, 5th Edition ).
Pharmaceutical Technology
JUNE 15, 2023
Drug development is already a difficult endeavor, with the vast majority of R&D efforts failing to produce a market-worthy product. Even reaching the clinical trial phase offers no guarantees, as only 12% of such drugs receive U.S. While this process is essential, it’s also slow, expensive and unpredictable.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
FEBRUARY 13, 2023
With all this in mind, how do drug developers know which strategy and approach is right for their molecule at this early stage? Key considerations in the candidate selection stage The first step in a drug development program is choosing the optimum molecule from a range of potential leads that have been optimized within drug discovery.
European Pharmaceutical Review
JULY 5, 2022
The availability of oral chemotherapy treatments would provide stomach cancer patients with the option of more efficacious drugs with improved tolerability in a more convenient dosage format” The poor clinical outcomes of stomach cancer make it a key target for drug development.
European Pharmaceutical Review
JUNE 28, 2022
billion by 2026, achieving a compound annual growth rate (CAGR) of 13.2 Advancements are underway in terms of product developments and innovations, with significant emphasis being placed on optimising and streamlining existing methods.
European Pharmaceutical Review
FEBRUARY 14, 2024
As previously highlighted batch-to-batch variability in potency is expected, however, the compounding effect of method related variability in quantification makes root cause analysis even more difficult when trying to identify those parameters/conditions for process establishment/scale up.
European Pharmaceutical Review
JUNE 24, 2022
The review was impacted by Brexit and the COVID-19 pandemic, which compounded existing issues surrounding high drug pricing and patient access that had been brewing since 2016 and highlighted several shortcomings in the EU’s pharmaceutical system. pocket expenses account for only seven percent of the overall cost of developing drugs.
Expert insights. Personalized for you.
98 
Let's personalize your content